Author: Stephen Erhorn

Formulary amendments August 2026 & horizon scanning September 2026

September 8, 2026

wo new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in March 2026:

Formulary amendments July 2026 & horizon scanning August 2026

September 2, 2026

wo new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in March 2026:

Formulary amendments June 2026 & horizon scanning July 2026

July 24, 2026

wo new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in March 2026:

Formulary amendments May 2026 & horizon scanning June 2026

June 23, 2026

wo new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in March 2026:

Formulary amendments April 2026 & horizon scanning May 2026

May 13, 2026

Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in April 2026:

Formulary amendments March 2026 & horizon scanning April 2026

April 24, 2026

Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in March 2026:

Formulary assessment – levodopa inhalation powder (Inbrija)

March 19, 2026

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

The information in this document is correct at the time of publication and formulations may change. This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

The Formulary Assessment tool for inhaled levodopa can be accessed here

Formulary amendments February 2026 & horizon scanning March 2026

Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in February 2026:

Switching from disposable to reusable insulin pens

March 17, 2026

This document outlines the benefits of appropriate switching from disposable to reusable insulin pens, highlighting advantages for patients, the environment, and potential cost savings. It also provides practical recommendations for implementation by medicines optimisation teams

The switching from disposable to reusable insulin pens bulletin can be accessed here

Electronic repeat dispensing (eRD): medicines roadmap and outcomes of high eRD uptake

March 11, 2026

Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System (ICS) leaders. Through the analysis of data and communication with key stakeholders across the ICS, interventions to be undertaken by the ICS are proposed to Integrated Care Boards or associated committees.

This report provides a medicines roadmap to support the uptake and implementation of electronic repeat dispensing (eRD). It also presents the results of an analysis on the impact of high levels of eRD implementation on prescribing volume and hospital admissions.

The eRD medicines roadmap strategic insight report can be accessed here